const Pubdata = [
  {
    congressName: "AAD",
    recent: true,
    id: 1,
    pubimg: "../img/icon1.png",
    pubtitle:
      "Recent 2022Ligelizumab achieves freedom from signs and symptoms of chronic spontaneous urticaria regardless of the CU index (basophil histamine release assay) status at baseline",
    pubauthors:
      "K. Sitz, J. A. Bernstein, W. Soong, M. Maurer, A. M. Giménez-Arnau, E. Hua, T. Severin author1",
    links: [
      {
        linkpath: "https://www.urticariaknowledgecenter.novartis.com/",
        linkclass: "abstract",
        linktext: "abstract",
      },
      {
        linkpath: "test.pdf",
        linkclass: "oral",
        linktext: "oral",
      },
      {
        linkpath: "test.pdf",
        linkclass: "poster",
        linktext: "Poster",
      },
    ],
  },
  {
    congressName: "AAD",
    id: 4,
    recent: true,
    pubimg: "../img/icon1.png",
    pubtitle:
      "2022Ligelizumab achieves freedom from signs and symptoms of chronic spontaneous urticaria regardless of the CU index (basophil histamine release assay) status at baseline",
    pubauthors:
      "K. Sitz, J. A. Bernstein, W. Soong, M. Maurer, A. M. Giménez-Arnau, E. Hua, T. Severin author2",
    links: [
      {
        linkpath: "https://www.urticariaknowledgecenter.novartis.com/",
        linkclass: "abstract",
        linktext: "abstract",
      },
      {
        linkpath: "test.pdf",
        linkclass: "oral",
        linktext: "oral",
      },
      {
        linkpath: "test.pdf",
        linkclass: "poster",
        linktext: "Poster",
      },
    ],
  },
  {
    congressName: "AAAAI",
    id: 2,
    pubimg: "../img/icon1.png",
    pubtitle:
      "2021 Ligelizumab achieves freedom from signs and symptoms of chronic spontaneous urticaria regardless of the CU index (basophil histamine release assay) status at baseline",
    pubauthors:
      "K. Sitz, J. A. Bernstein, W. Soong, M. Maurer, A. M. Giménez-Arnau, E. Hua, T. Severin author3",
    links: [
      {
        linkpath: "google.com",
        linkclass: "abstract",
        linktext: "abstract",
      },
      {
        linkpath: "test.pdf",
        linkclass: "oral",
        linktext: "oral",
      },
      {
        linkpath: "test.pdf",
        linkclass: "poster",
        linktext: "Poster",
      },
    ],
  },
  {
    congressName: "AAAAI",
    id: 5,
    pubimg: "../img/icon1.png",
    pubtitle:
      "2021 Ligelizumab achieves freedom from signs and symptoms of chronic spontaneous urticaria regardless of the CU index (basophil histamine release assay) status at baseline",
    pubauthors:
      "K. Sitz, J. A. Bernstein, W. Soong, M. Maurer, A. M. Giménez-Arnau, E. Hua, T. Severin author4",
    links: [
      {
        linkpath: "google.com",
        linkclass: "abstract",
        linktext: "abstract",
      },
      {
        linkpath: "test.pdf",
        linkclass: "oral",
        linktext: "oral",
      },
      {
        linkpath: "test.pdf",
        linkclass: "poster",
        linktext: "Poster",
      },
    ],
  },
  {
    congressName: "AAN",
    id: 6,
    recent: true,
    pubimg: "../img/icon1.png",
    pubtitle:
      "2021 Ligelizumab achieves freedom from signs and symptoms of chronic spontaneous urticaria regardless of the CU index (basophil histamine release assay) status at baseline",
    pubauthors:
      "K. Sitz, J. A. Bernstein, W. Soong, M. Maurer, A. M. Giménez-Arnau, E. Hua, T. Severin author4",
    links: [
      {
        linkpath: "google.com",
        linkclass: "abstract",
        linktext: "abstract",
      },
      {
        linkpath: "test.pdf",
        linkclass: "oral",
        linktext: "oral",
      },
      {
        linkpath: "test.pdf",
        linkclass: "poster",
        linktext: "Poster",
      },
    ],
  },
];

export { Pubdata };
